Citations

Mayo Clinic

Showing 10 of 108572 citations.

Left ventricular non-compaction cardiomyopathy: Incidental diagnosis after ST-elevation myocardial infarction
Liang, Jackson J. , Fenstad, Eric R. , Janish, Christopher D., Sinak, Lawrence J., Liang, Jackson

Acute Cardiac Care | October 18, 2016 | Volume: 18 | Issue: 1 | Pages: 25-27

10.1080/17482941.2016.1234055 | PMID 27754701 Get It

Sex Differences in Fractional Flow Reserve-Guided Revascularization: A Nationwide Analysis
Lakhter, Vladimir , Zack, Chad, Cohen, Howard, O’Neill, Brian P. , O’Murchu, Brian, Bové, Alfred A., Bashir, Riyaz , Zack, Chad J, Alkhouli, Mohamad , Zhao, Huaqing

Journal of Women's Health | October 18, 2016 | Volume: 26 | Issue: 2 | Pages: 109-115

10.1089/jwh.2016.5806 | PMID 27754754 Get It

Immunotherapy in pancreatic cancer treatment: a new frontier
Thind, Komal, Padrnos, Leslie , Ramanathan, Ramesh K., Padrnos, Leslie J, Borad, Mitesh J.

Therapeutic Advances in Gastroenterology | October 18, 2016 | Volume: 10 | Issue: 1 | Pages: 168-194

10.1177/1756283x16667909 | PMID 28286568 Get It

Pancreatic cancer is a highly aggressive and lethal cancer characterized by high invasiveness, local and extensive dissemination at time of diagnosis and resistance to treatment. Few therapies have shown efficacy in the past and even standard of care therapies yield only modest improvements in the mortality of patients with advanced or metastatic disease. Efforts have been undertaken to study the pancreatic tumor microenvironment and have established its complex and immunosuppressive nature which could explain the high resistance to chemotherapy. Novel therapies targeting the tumor microenvironment with an aim to decrease this resistance, improve immune tolerance and increase the efficacy of the current treatment have shown some promising preliminary results in preclinical and clinical trials. We review the current advances in the field of immunotherapy and their effectiveness as a potential treatment strategy in the pancreatic cancer.
MACRA and the future of value-based care
Jones, Lyell K. , Raphaelson, Marc, Becker, Amanda, Kaloides, Amy, Scharf, Eugene , Jones, Lyell K

Neurology Clinical Practice | October 18, 2016 | Volume: 6 | Issue: 5 | Pages: 459-465

10.1212/cpj.0000000000000296 | PMID 29443269 Get It

Primary biliary cirrhosis has high wait-list mortality among patients listed for liver transplantation
Kaif, Mohamed, Hasanin, Mohsen, McGuire, Brendan M. , Kuo, Yong‐Fang , Wiesner, Russell H., Singal, Ashwani K. , Fang, Xiao

Transplant International | October 18, 2016 | Volume: 30 | Issue: 5 | Pages: 454-462

10.1111/tri.12877 | PMID 27754570 Get It

Noninvasive Ventilation of Patients with Acute Respiratory Distress Syndrome. Insights from the LUNG SAFE Study
Laffey, John G. , Pham, Tài , Madotto, Fabiana , Brochard, Laurent , Esteban, Andres, Gattinoni, Luciano , Bumbaširević, Vesna, Piquilloud, Lise , Haren, Frank van , Larsson, Anders, McAuley, Daniel F. , Arabi, Yaseen M. , Ranieri, Marco, Antonelli, Massimo , Rubenfeld, Gordon D., Wrigge, Hermann , Slutsky, Arthur S. , Schultz, Marcus J. , Bajwa, Ednan K. , Ferguson, Niall D. , Frendl, György , Brown, Samuel M. , Terzi, Nicolas , Brazzi, Luca , Montini, Luca , Tomescu, Dana , Lanspa, Michael J. , Almekhlafi, Ghaleb A. , Cortegiani, Andrea , Fusari, Maurizio , González-Castro, A. , Parotto, Matteo , Sánchez‐Hurtado, Luis Alejandro , Spadaro, Savino , Szakmány, Tamás , Zani, Gianluca , Bihari, Shailesh , Laffey, John G , Bellani, Giacomo , Fan, Eddy , Esteban, Andres, Bauer, Philippe R. , Thompson, Bruce , Pesenti, Antonio Maria , Schultz, Marcus J , Arabi, Yaseen M

American Journal of Respiratory and Critical Care Medicine | October 18, 2016 | Volume: 195 | Issue: 1 | Pages: 67-77

10.1164/rccm.201606-1306oc | PMID 27753501 Get It

Abstract Rationale Noninvasive ventilation (NIV) is increasingly used in patients with acute respiratory distress syndrome (ARDS). The evidence supporting NIV use in patients with ARDS remains relatively sparse. Objectives To determine whether, during NIV, the categorization of ARDS severity based on the PaO2/FiO2 Berlin criteria is useful. Methods The LUNG SAFE (Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure) study described the management of patients with ARDS. This substudy examines the current practice of NIV use in ARDS, the utility of the PaO2/FiO2 ratio in classifying patients receiving NIV, and the impact of NIV on outcome. Measurements and Main Results Of 2,813 patients with ARDS, 436 (15.5%) were managed with NIV on Days 1 and 2 following fulfillment of diagnostic criteria. Classification of ARDS severity based on PaO2/FiO2 ratio was associated with an increase in intensity of ventilatory support, NIV failure, and intensive care unit (ICU) mortality. NIV failure occurred in 22.2% of mild, 42.3% of moderate, and 47.1% of patients with severe ARDS. Hospital mortality in patients with NIV success and failure was 16.1% and 45.4%, respectively. NIV use was independently associated with increased ICU (hazard ratio, 1.446 [95% confidence interval, 1.159–1.805]), but not hospital, mortality. In a propensity matched analysis, ICU mortality was higher in NIV than invasively ventilated patients with a PaO2/FiO2 lower than 150 mm Hg. Conclusions NIV was used in 15% of patients with ARDS, irrespective of severity category. NIV seems to be associated with higher ICU mortality in patients with a PaO2/FiO2 lower than 150 mm Hg. Clinical trial registered with www.clinicaltrials.gov (NCT 02010073).
Anterior Cingulate Glutamate Is Reduced by Acamprosate Treatment in Patients With Alcohol Dependence
Frye, Mark A. , Hinton, David J., Karpyak, Victor M. , Gunderson, Lee J., Feeder, Scott E., Port, John D. , Biernacka, Joanna M. , Choi, Doo‐Sup , Port, John D , Karpyak, Victor

Journal of Clinical Psychopharmacology | October 18, 2016 | Volume: 36 | Issue: 6 | Pages: 669-674

10.1097/jcp.0000000000000590 | PMID 27755217 Get It

Abstract Although the precise drug mechanism of action of acamprosate remains unclear, its antidipsotropic effect is mediated in part through glutamatergic neurotransmission. We evaluated the effect of 4 weeks of acamprosate treatment in a cohort of 13 subjects with alcohol dependence (confirmed by a structured interview, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision) on proton magnetic resonance spectroscopy glutamate levels in the midline anterior cingulate cortex (MACC). We compared levels of metabolites with a group of 16 healthy controls. The Pennsylvania Alcohol Craving Scale was used to assess craving intensity. At baseline, before treatment, the mean cerebrospinal fluid–corrected MACC glutamate (Glu) level was significantly elevated in subjects with alcohol dependence compared with controls (P = 0.004). Four weeks of acamprosate treatment reduced glutamate levels (P = 0.025), an effect that was not observed in subjects who did not take acamprosate. At baseline, there was a significant positive correlation between cravings, measured by the Pennsylvania Alcohol Craving Scale, and MACC (Glu) levels (P = 0.019). Overall, these data would suggest a normalizing effect of acamprosate on a hyperglutamatergic state observed in recently withdrawn patients with alcohol dependence and a positive association between MACC glutamate levels and craving intensity in early abstinence. Further research is needed to evaluate the use of these findings for clinical practice, including monitoring of craving intensity and individualized selection of treatment with antidipsotropic medications in subjects with alcohol dependence.
Three-dimensional printed models in multidisciplinary planning of complex tracheal reconstruction
Balakrishnan, Karthik , Cofer, Shelagh A. , Matsumoto, Jane M., Dearani, Joseph A. , Boesch, R. Paul , Cofer, Shelagh, Dearani, Joseph A. , Balakrishnan, Karthik

The Laryngoscope | October 18, 2016 | Volume: 127 | Issue: 4 | Pages: 967-970

10.1002/lary.26353 | PMID 27753107 Get It

The New Prostate Cancer Grading System Does Not Improve Prediction of Clinical Recurrence After Radical Prostatectomy: Results of a Large, Two‐Center Validation Study
Karnes, R. Jeffrey , Gandaglia, Giorgio , Stabile, Armando , Moschini, Marco , Cucchiara, Vito , Zaffuto, Emanuele , Karakiewicz, Pierre I. , Suardi, Nazareno , Montorsi, Francesco , Briganti, Alberto , Larcher, Alessandro , Karnes, Robert Jeffrey, Dell’Oglio, Paolo , Fossati, Nicola , Zaffuto, Emanuele , Stabile, Armando , Moschini, Marco

The Prostate | October 18, 2016 | Volume: 77 | Issue: 3 | Pages: 263-273

10.1002/pros.23265 | PMID 27753114 Get It

BACKGROUNDA new prostate cancer (PCa) grading system (namely, Gleason score‐GS‐ ≤6 vs. 3 + 4 vs. 4 + 3 vs. 8 vs. ≥9) was recently proposed and assessed on biochemical recurrence (BCR) showing improved predictive abilities compared to the commonly used three‐tier system (GS ≤6 vs. 7 vs. ≥8). We assessed the predictive ability of the five‐tier grade group (GG) system on harder clinical endpoint, namely clinical recurrence (CR).METHODSBetween 2005 and 2014, 9,728 clinically localized PCa patients were treated with radical prostatectomy (RP) at two tertiary referral centers. Kaplan–Meier curves, multivariable Cox regression analyses, and concordance index (C‐index) were used to assess CR after treatment according to four Gleason grade classifications at biopsy and RP: Group 1: ≤6 versus 7 versus ≥8; Group 2: ≤6 versus 3 + 4 vs. 4 + 3 versus ≥8; Group 3: ≤6 versus 7 versus 8 versus ≥9; Group 4: ≤6 versus 3 + 4 versus 4 + 3 versus 8 versus ≥9. Same analyses were repeated in patients who had BCR (n = 1,624). Decision curve analyses were performed to evaluate and compare the net benefit associated with the use of the four Gleason grade classifications.RESULTSOverall, 443 (4.6%) patients had CR. The hazard ratio of the GS 3 + 4, 4 + 3, 8, and ≥9 relative to GS ≤6 were 3.63, 5.93, 11.44, 18.08 and 4.93, 9.99, 15.31 and 25.12 in the pre‐ and post‐treatment models, respectively. The C‐index of the five‐tier GG system was slightly higher relative to the other 3 Gleason grade classifications both in the pre‐ (range: 0.001–0.006) and post‐treatment models (range: 0–0.008). Similar findings were observed when we focused our analyses in patients with BCR after RP. The use of the five‐tier GG system did not result into higher net‐benefit relative to the other three Gleason grade classifications.CONCLUSIONSThe difference in accuracy between the five‐tier GG system and the other Gleason grade classifications, using CR as an endpoint, is clinically negligible. Current evidence suggests that the five‐tier GG system represents a simplified user‐friendly scheme available for patient counseling rather than a new histopathological diagnostic system that improves the prediction of CR. Prostate 77:263–273, 2017. © 2016 Wiley Periodicals, Inc.
Factors associated with regional recurrence after lymph node dissection for penile squamous cell carcinoma
Reddy, Jay P. , Pettaway, Curtis A. , Levy, Lawrence B., Pagliaro, Lance C. , Tamboli, Pheroze, Jayaratna, Isuru, Hoffman, Karen E. , Reddy, Jay P , Rao, Priya

BJU International | October 18, 2016 | Volume: 119 | Issue: 4 | Pages: 591-597

10.1111/bju.13686 | PMID 27753187 Get It

Objective To identify factors associated with regional recurrence after lymph node dissection ( LND ) for squamous cell carcinoma ( SCC ) to determine which patients might benefit from adjuvant therapy. Patients and Methods Men who underwent LND for penile SCC from 1977 to 2014 were identified from an institutional database. Kaplan–Meier curves estimated recurrence‐free survival ( RFS ) calculated from the date of LND . Cox regression models evaluated the association between RFS and patient and tumour characteristics. Results In all, 182 men who underwent LND for penile SCC were identified. The median patient age was 62 years and the median follow‐up was 4.2 years. After LND 34 men had regional recurrence, of which 24 developed isolated regional recurrences without distant metastasis. The median RFS was 5.7 months, and the 3‐year RFS rate was 70%. On univariate analysis, lymphovascular invasion, clinical and pathological nodal stage, pathological inguinal laterality, pelvic nodal involvement, lymph node density ≥5.2%, ≥3 pathologically involved lymph nodes, and extranodal extension ( ENE ) were associated with worse RFS (all P < 0.05). On multivariate analysis, clinical N3 disease [adjusted hazard ratio ( AHR )] 3.53, 95% confidence interval ( CI ) 1.68–7.45; P = 0.001), ≥3 pathologically involved lymph nodes ( AHR 3.78, 95% CI 2.12–6.65; P < 0.001), and ENE ( AHR 3.32, 95% CI 1.93–5.76; P < 0.001) were associated with worse RFS . The 3‐year RFS for patients with cN 0, cN 1, cN 2, and cN 3 disease was 91.7%, 64.5%, 54.7%, and 38.3%, respectively. For men with ≥3 involved nodes, the 3‐year RFS was 17% vs 82.4% in men with <3 involved nodes. The 3‐year RFS was 29.7% in men with ENE and 85.7% in men without ENE. Conclusion The presence of clinical N3 disease, ≥3 pathologically involved lymph nodes, and ENE was associated with worse RFS . As regional recurrence portends a dismal prognosis with few salvage options, adjuvant therapies should be developed for men with the aforementioned adverse factors.